Clinical significance of various drug-sensitivity markers in patients with surgically resected pulmonary pleomorphic carcinoma

Hisao Imai, Kimihiro Shimizu, Osamu Kawashima, Hideki Endoh, Kazuyoshi Imaizumi, Yasuhiro Goto, Mitsuhiro Kamiyoshihara, Masayuki Sugano, Ryohei Yamamoto, Shigebumi Tanaka, Atsushi Fujita, Yoshihito Kogure, Yukio Seki, Akira Mogi, Tetsunari Oyama, Koichi Minato, Takayuki Asao, Kyoichi Kaira

Research output: Contribution to journalArticle

Abstract

Various drug-sensitivity markers are potentially responsible for tumor progression and chemotherapy resistance in cancer patients with both epithelial and sarcomatous components; however, the clinicopathological significance of drug-sensitivity markers in patients with pulmonary pleomorphic carcinoma (PPC) remains unknown. Here, we clarified the prognostic impact of these drug-sensitivity markers in PPC by performing immunohistochemical and clinicopathologic analyses of samples from 105 patients with surgically resected PPC in order to evaluate levels of vascular endothelial growth factor 2 (VEGFR2), stathmin 1 (STMN1), tubulin β3 class III (TUBB3), thymidylate synthetase (TS), topoisomerase II (Topo-II), glucose-regulated protein, and 78 kDa (GRP78)/binding immunoglobulin protein (BiP). We observed the rates of high expression for VEGFR2, STMN1, TUBB3, TS, Topo-II, and GRP78/BiP were 33% (39/105), 35% (37/105), 61% (64/105), 51% (53/105), 31% (33/105), and 51% (53/105) of the samples, respectively. Moreover, multivariate analysis identified VEGFR2 and GRP78/BiP as significant independent markers for predicting worse prognosis. These findings suggested elevated VEGFR2 and decreased GRP78/BiP levels as independent factors for predicting poor outcomes following surgical resection in patients with PPC.

Original languageEnglish
Article number1636
JournalCancers
Volume11
Issue number11
DOIs
Publication statusPublished - 11-2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical significance of various drug-sensitivity markers in patients with surgically resected pulmonary pleomorphic carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Imai, H., Shimizu, K., Kawashima, O., Endoh, H., Imaizumi, K., Goto, Y., Kamiyoshihara, M., Sugano, M., Yamamoto, R., Tanaka, S., Fujita, A., Kogure, Y., Seki, Y., Mogi, A., Oyama, T., Minato, K., Asao, T., & Kaira, K. (2019). Clinical significance of various drug-sensitivity markers in patients with surgically resected pulmonary pleomorphic carcinoma. Cancers, 11(11), [1636]. https://doi.org/10.3390/cancers11111636